Glenmark Pharmaceuticals has received final USFDA approval for Atovaquone, used for prevention and treatment of a type of pneumonia. The drug Atovaquone Oral Suspension USP in the strength of 750 mg/5 million is a generic version of GlaxoSmithKline’s Mepron Oral Suspension of similar strength. According to market estimates, Mepron Oral Suspension market achieved annual sales of approximately USD 119.1 million.
The company’s current portfolio consists of 144 products authorized for distribution in the US marketplace and 55 abbreviated new drug applications (ANDAs) pending approval with the USFDA.
Company Profile : Glenmark Pharma Ltd
Leave a Reply